These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 30374417)

  • 1. Iron Chelation with Transdermal Deferoxamine Accelerates Healing of Murine Sickle Cell Ulcers.
    Rodrigues M; Bonham CA; Minniti CP; Gupta K; Longaker MT; Gurtner GC
    Adv Wound Care (New Rochelle); 2018 Oct; 7(10):323-332. PubMed ID: 30374417
    [No Abstract]   [Full Text] [Related]  

  • 2. Transdermal deferoxamine administration improves excisional wound healing in chronically irradiated murine skin.
    Lintel H; Abbas DB; Lavin CV; Griffin M; Guo JL; Guardino N; Churukian A; Gurtner GC; Momeni A; Longaker MT; Wan DC
    J Transl Med; 2022 Jun; 20(1):274. PubMed ID: 35715816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of transdermal deferoxamine leads to enhanced efficacy in healing skin wounds.
    Duscher D; Trotsyuk AA; Maan ZN; Kwon SH; Rodrigues M; Engel K; Stern-Buchbinder ZA; Bonham CA; Barrera J; Whittam AJ; Hu MS; Inayathullah M; Rajadas J; Gurtner GC
    J Control Release; 2019 Aug; 308():232-239. PubMed ID: 31299261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transdermal deferoxamine prevents pressure-induced diabetic ulcers.
    Duscher D; Neofytou E; Wong VW; Maan ZN; Rennert RC; Inayathullah M; Januszyk M; Rodrigues M; Malkovskiy AV; Whitmore AJ; Walmsley GG; Galvez MG; Whittam AJ; Brownlee M; Rajadas J; Gurtner GC
    Proc Natl Acad Sci U S A; 2015 Jan; 112(1):94-9. PubMed ID: 25535360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.
    Jordan LB; Vekeman F; Sengupta A; Corral M; Guo A; Duh MS
    J Clin Pharm Ther; 2012 Apr; 37(2):173-81. PubMed ID: 21592159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healing of chronic sickle cell disease-associated foot and ankle wounds using transdermal continuous oxygen therapy.
    Massenburg BB; Himel HN
    J Wound Care; 2016 Feb; 25(2):S23-4, S26-7. PubMed ID: 26878371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deferoxamine can prevent pressure ulcers and accelerate healing in aged mice.
    Bonham CA; Rodrigues M; Galvez M; Trotsyuk A; Stern-Buchbinder Z; Inayathullah M; Rajadas J; Gurtner GC
    Wound Repair Regen; 2018 May; 26(3):300-305. PubMed ID: 30152571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programs.
    Armstrong EP; Skrepnek GH; Sasane M; Snodgrass SM; Ballas SK
    J Med Econ; 2013; 16(1):10-8. PubMed ID: 22947171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deferoxamine enhances neovascularization and accelerates wound healing in diabetic rats via the accumulation of hypoxia-inducible factor-1α.
    Hou Z; Nie C; Si Z; Ma Y
    Diabetes Res Clin Pract; 2013 Jul; 101(1):62-71. PubMed ID: 23726275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer's Disease, Parkinson's Disease, and Intracerebral Hemorrhage.
    Farr AC; Xiong MP
    Mol Pharm; 2021 Feb; 18(2):593-609. PubMed ID: 32926630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deferoxamine topical cream superior to patch in rescuing radiation-induced fibrosis of unwounded and wounded skin.
    Berry CE; Abbas DB; Griffin M; Lintel H; Guo J; Kameni L; Churukian AA; Fazilat AZ; Chen K; Gurtner GC; Longaker MT; Momeni A; Wan DC
    J Cell Mol Med; 2024 Apr; 28(8):e18306. PubMed ID: 38613357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deferoxamine to Minimize Fibrosis During Radiation Therapy.
    Tevlin R; Longaker MT; Wan DC
    Adv Wound Care (New Rochelle); 2022 Oct; 11(10):548-559. PubMed ID: 34074152
    [No Abstract]   [Full Text] [Related]  

  • 14. Co-delivery of deferoxamine and hydroxysafflor yellow A to accelerate diabetic wound healing via enhanced angiogenesis.
    Gao SQ; Chang C; Li JJ; Li Y; Niu XQ; Zhang DP; Li LJ; Gao JQ
    Drug Deliv; 2018 Nov; 25(1):1779-1789. PubMed ID: 30338719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Injectable Desferrioxamine-Laden Silk Nanofiber Hydrogels for Accelerating Diabetic Wound Healing.
    Ding Z; Zhang Y; Guo P; Duan T; Cheng W; Guo Y; Zheng X; Lu G; Lu Q; Kaplan DL
    ACS Biomater Sci Eng; 2021 Mar; 7(3):1147-1158. PubMed ID: 33522800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.
    McLeod C; Fleeman N; Kirkham J; Bagust A; Boland A; Chu P; Dickson R; Dundar Y; Greenhalgh J; Modell B; Olujohungbe A; Telfer P; Walley T
    Health Technol Assess; 2009 Jan; 13(1):iii-iv, ix-xi, 1-121. PubMed ID: 19068191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deferoxamine Intradermal Delivery Patch for Treatment of a Beta-Thalassemia Wound.
    Perrault D; Chattopadhyay A; Sivaraj D; Wan D; Chen K; Gurtner G; Sen S
    Ann Surg Open; 2024 Mar; 5(1):e372. PubMed ID: 38883943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iron chelation cancer therapy using hydrophilic block copolymers conjugated with deferoxamine.
    Komoto K; Nomoto T; El Muttaqien S; Takemoto H; Matsui M; Miura Y; Nishiyama N
    Cancer Sci; 2021 Jan; 112(1):410-421. PubMed ID: 32770631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of iron chelating agent on Schistosoma mansoni infected murine model.
    Abdelgelil NH; Abdellatif MZM; Abdel-Hafeez EH; Belal US; Mohamed RM; Abdel-Razik AH; Hassanin KMA; Abdel-Wahab A
    Biomed Pharmacother; 2019 Jan; 109():28-38. PubMed ID: 30391706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
    Fortin PM; Fisher SA; Madgwick KV; Trivella M; Hopewell S; Doree C; Estcourt LJ
    Cochrane Database Syst Rev; 2018 May; 5(5):CD012349. PubMed ID: 29737522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.